Please wait while the formulary information is being retrieved.
Drug overview for TRIAZOLAM (triazolam):
Generic name: TRIAZOLAM (tri-AH-zoe-lam)
Drug class: Benzodiazepines
Therapeutic class: Central Nervous System Agents
Triazolam is a benzodiazepine.
Triazolam shares the actions of other benzodiazepines and is used as a hypnotic agent in the short-term treatment of insomnia generally for periods not exceeding 7-10 days in duration. The failure of insomnia to remit after 7-10 days of triazolam therapy may indicate the presence of an underlying psychiatric and/or medical condition. Continued use of the drug for longer than 2-3 weeks usually is not indicated and should be undertaken only upon further evaluation of the patient. The possibility that insomnia may be a symptom of an underlying condition for which there may be a more specific treatment should be considered.
Generic name: TRIAZOLAM (tri-AH-zoe-lam)
Drug class: Benzodiazepines
Therapeutic class: Central Nervous System Agents
Triazolam is a benzodiazepine.
Triazolam shares the actions of other benzodiazepines and is used as a hypnotic agent in the short-term treatment of insomnia generally for periods not exceeding 7-10 days in duration. The failure of insomnia to remit after 7-10 days of triazolam therapy may indicate the presence of an underlying psychiatric and/or medical condition. Continued use of the drug for longer than 2-3 weeks usually is not indicated and should be undertaken only upon further evaluation of the patient. The possibility that insomnia may be a symptom of an underlying condition for which there may be a more specific treatment should be considered.
DRUG IMAGES
TRIAZOLAM 0.125 MG TABLET
TRIAZOLAM 0.25 MG TABLET
The following indications for TRIAZOLAM (triazolam) have been approved by the FDA:
Indications:
Insomnia
Professional Synonyms:
Agrypnia
Ahypnia
Indications:
Insomnia
Professional Synonyms:
Agrypnia
Ahypnia
The following dosing information is available for TRIAZOLAM (triazolam):
Dosage of triazolam must be individualized, and the smallest effective dosage should be used (especially in geriatric and/or debilitated patients or in those with liver disease or low serum albumin). Prolonged administration of triazolam should be avoided.
Because of the risk associated with prolonged triazolam therapy and the need for periodic reevaluation of the patient's condition, prescriptions for the drug should be written only for short-term (7-10 days) use and the quantity dispensed to the patient should not exceed a 1-month supply. In addition, to ensure safe and effective use of triazolam, patients should be given a copy of the patient information provided by the manufacturers and the contents of this information should be discussed with them. To aid in complying with these recommendations, triazolam is commercially available in unit-of-use packaging that contains a supply of only 10 tablets of the drug and the patient information.
The usual adult dose of triazolam is 0.25 mg; a dose of 0.125 mg may be adequate for some patients (e.g., those with low body weight).
A dose of 0.5 mg should be reserved for exceptional cases in which the patient does not respond adequately to a lower dose, since the risk of some adverse effects increases with increasing dose; a 0.5-mg dose should not be exceeded.
In geriatric and/or debilitated patients, an initial triazolam dose of 0.125 mg should be used. While the usual dose in patients generally ranges from 0.125-0.25
mg, a dose of 0.25 mg should be reserved for exceptional cases in which the patient does not respond adequately to a lower dose, since geriatric patients are particularly susceptible to dose-related adverse effects of the drug. The pharmacokinetics (peak plasma concentration, area under the plasma concentration-time curve, clearance) and dose-related effects (sedation, psychomotor performance) of single doses of triazolam suggest that usual dosages in otherwise healthy geriatric patients should be approximately half those in younger adults.
(See Pharmacokinetics: Elimination, in the Benzodiazepines General Statement 28:24.08.) In addition, epidemiologic evidence suggests that the risk of adverse (e.g., behavioral) effects is increased when therapy is initiated in geriatric patients at doses exceeding 0.125 mg.
In patients who have received prolonged triazolam therapy, abrupt discontinuance of the drug should be avoided since manifestations of withdrawal can be precipitated. While the risk and severity of withdrawal manifestations are increased as the duration and dose increase, such manifestations can occur at usual doses given for relatively short periods (e.g., 1-2 weeks) and occasionally between nightly doses. Therefore, if the drug is to be discontinued in any patient receiving more than the lowest dose for longer than a few weeks, it is recommended that dosage be tapered gradually.
Gradual tapering is particularly important in patients with a seizure history. There also is evidence that abrupt discontinuance of triazolam after relatively short periods of therapy (e.g., 1 week) can result in rebound insomnia, which generally persists for one or two nights. Therefore, some clinicians suggest that gradual dosage reduction (e.g., over several nights) also be considered when discontinuing short-term triazolam therapy, since the development of rebound insomnia can perpetuate continued use of hypnotics in patients with insomnia.
Because of the risk associated with prolonged triazolam therapy and the need for periodic reevaluation of the patient's condition, prescriptions for the drug should be written only for short-term (7-10 days) use and the quantity dispensed to the patient should not exceed a 1-month supply. In addition, to ensure safe and effective use of triazolam, patients should be given a copy of the patient information provided by the manufacturers and the contents of this information should be discussed with them. To aid in complying with these recommendations, triazolam is commercially available in unit-of-use packaging that contains a supply of only 10 tablets of the drug and the patient information.
The usual adult dose of triazolam is 0.25 mg; a dose of 0.125 mg may be adequate for some patients (e.g., those with low body weight).
A dose of 0.5 mg should be reserved for exceptional cases in which the patient does not respond adequately to a lower dose, since the risk of some adverse effects increases with increasing dose; a 0.5-mg dose should not be exceeded.
In geriatric and/or debilitated patients, an initial triazolam dose of 0.125 mg should be used. While the usual dose in patients generally ranges from 0.125-0.25
mg, a dose of 0.25 mg should be reserved for exceptional cases in which the patient does not respond adequately to a lower dose, since geriatric patients are particularly susceptible to dose-related adverse effects of the drug. The pharmacokinetics (peak plasma concentration, area under the plasma concentration-time curve, clearance) and dose-related effects (sedation, psychomotor performance) of single doses of triazolam suggest that usual dosages in otherwise healthy geriatric patients should be approximately half those in younger adults.
(See Pharmacokinetics: Elimination, in the Benzodiazepines General Statement 28:24.08.) In addition, epidemiologic evidence suggests that the risk of adverse (e.g., behavioral) effects is increased when therapy is initiated in geriatric patients at doses exceeding 0.125 mg.
In patients who have received prolonged triazolam therapy, abrupt discontinuance of the drug should be avoided since manifestations of withdrawal can be precipitated. While the risk and severity of withdrawal manifestations are increased as the duration and dose increase, such manifestations can occur at usual doses given for relatively short periods (e.g., 1-2 weeks) and occasionally between nightly doses. Therefore, if the drug is to be discontinued in any patient receiving more than the lowest dose for longer than a few weeks, it is recommended that dosage be tapered gradually.
Gradual tapering is particularly important in patients with a seizure history. There also is evidence that abrupt discontinuance of triazolam after relatively short periods of therapy (e.g., 1 week) can result in rebound insomnia, which generally persists for one or two nights. Therefore, some clinicians suggest that gradual dosage reduction (e.g., over several nights) also be considered when discontinuing short-term triazolam therapy, since the development of rebound insomnia can perpetuate continued use of hypnotics in patients with insomnia.
Triazolam is administered orally at bedtime. Concomitant oral administration of triazolam with grapefruit juice should be avoided since grapefruit juice has been reported to increase bioavailability of triazolam. (See Drug Interactions: Grapefruit Juice in the Benzodiazepines General Statement 28:24.08.)
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| TRIAZOLAM 0.25 MG TABLET | Maintenance | Adults take 1 tablet (0.25 mg) by oral route once daily at bedtime as needed |
| TRIAZOLAM 0.125 MG TABLET | Maintenance | Adults take 1 tablet (0.125 mg) by oral route once daily at bedtime as needed |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| TRIAZOLAM 0.125 MG TABLET | Maintenance | Adults take 1 tablet (0.125 mg) by oral route once daily at bedtime as needed |
| TRIAZOLAM 0.25 MG TABLET | Maintenance | Adults take 1 tablet (0.25 mg) by oral route once daily at bedtime as needed |
The following drug interaction information is available for TRIAZOLAM (triazolam):
There are 6 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Protease Inhibitors/Oral Midazolam; Triazolam SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The protease inhibitors may inhibit the metabolism of the benzodiazepines midazolam and triazolam at CYP3A4.(1-30) CLINICAL EFFECTS: Concurrent administration may result in increased levels and clinical effects of the benzodiazepines, which may result in profound sedation, respiratory depression, coma, and/or death.(1-30) Higher triazolam levels may increase risk for anterograde amnesia, "sleep driving" and other complex behavior disorders.(30) PREDISPOSING FACTORS: The elderly are particularly sensitive to increased plasma concentrations of triazolam.(30) PATIENT MANAGEMENT: The manufacturers of the protease inhibitors and US guidelines on use of antiretroviral agents (31) state that concurrent administration of triazolam or oral midazolam with ritonavir-boosted(1-3) darunavir,(4-6) lopinavir,(7-9) nirmatrelvir,(10) paritaprevir,(11) saquinavir,(12-14) or tipranavir (15-17); ritonavir-boosted or unboosted amprenavir,(18-19) atazanavir,(20-21) fosamprenavir,(22-23) indinavir,(24-26); or nelfinavir,(27-29) is contraindicated. Midazolam may be administered by the intravenous route in patients with close clinical monitoring for respiratory depression and/or prolonged sedation. Caution should be exercised and dosage adjustments should be considered if these effects occur. DISCUSSION: In an open-label, randomized study in 14 subjects, lopinavir/ ritonavir (400/100 mg twice daily) decreased the metabolism of single doses of oral and intravenous midazolam (0.025 mg/kg and 5 mg, respectively) by 77% and 92%, respectively.(32) In a double-blind, randomized, cross-over study in 12 subjects, concurrent administration of saquinavir base with oral midazolam increased the bioavailability of oral midazolam from 41% to 90%. The midazolam maximum concentration (Cmax) and area-under-curve (AUC) increased two-fold and five-fold, respectively. The concurrent administration of saquinavir base with intravenous midazolam resulted in a decrease in midazolam clearance by 56% and increased the midazolam half-life from 4.1 hours to 9.5 hours.(33) In a study in 6 healthy subjects, saquinavir base (1200 mg twice daily) increased the AUC and Cmax of a single dose of midazolam (7.5 mg) by 514% and 235%, respectively.(12) In a study in 16 healthy subjects, saquinavir/ritonavir (1000/100 mg twice daily) increased the AUC and Cmax of a single dose of midazolam (7.5 mg) by 1144% and 327%, respectively.(14) In a double-blind study, ritonavir (four doses of 200 mg) decreased the clearance of a single dose of triazolam (0.125 mg) by 96%.(34) Amprenavir,(35), lopinavir,(36) and ritonavir(33,34) have been shown to inhibit triazolam metabolism in vitro in human liver microsomes. In a clinical trial of 13 healthy patients patients receiving concurrent midazolam (3mg) and ritonavir (100 mg three times daily), midazolam AUC increased by a factor of 28.4 +/- 4.2 and oral clearance was reduced to 4.2% of normal.(37) Protease inhibitors linked to this monograph include: amprenavir, atazanavir, fosamprenavir, darunavir, indinavir, lopinavir, nelfinavir, nirmatrelvir, paritaprevir, saquinavir, and tipranavir. Ritonavir, as a pharmacokinetic booster, will alert through the primary protease inhibitor. |
APTIVUS, ATAZANAVIR SULFATE, DARUNAVIR, EVOTAZ, FOSAMPRENAVIR CALCIUM, KALETRA, LOPINAVIR-RITONAVIR, PAXLOVID, PREZISTA, REYATAZ, VIRACEPT |
| Itraconazole; Ketoconazole; Levoketoconazole/Selected Benzodiazepines SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Itraconazole, ketoconazole, and levoketoconazole may inhibit the metabolism of alprazolam, estazolam, midazolam, and triazolam by CYP3A.(1-29) CLINICAL EFFECTS: Inhibition of benzodiazepine metabolism may produce increased levels of these agents, as well as increased clinical effects. Toxic effects of increased benzodiazepine levels include profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of alprazolam,(1) estazolam,(2) or triazolam(3-5) with itraconazole or ketoconazole or levoketoconazole is contraindicated. The concurrent use of oral midazolam with itraconazole(3) or ketoconazole(4) is contraindicated by the manufacturer of the azole antifungals. The manufacturer of oral midazolam states that the agents should only be used concurrently if absolutely necessary and if appropriate equipment and personnel are available to respond to respiratory insufficiency.(6) The concurrent use of injectable midazolam and itraconazole(3,7) or ketoconazole(4,7) should be approached with special precaution and patient monitoring. The US manufacturer of itraconazole states that concomitant administration with triazolam or oral midazolam is contraindicated during and two weeks after itraconazole treatment.(3) The US manufacturer of levoketoconazole states concurrent use with sensitive CYP3A4 substrates is contraindicated.(29) DISCUSSION: In a double-blind cross-over study in 10 healthy subjects, itraconazole increased alprazolam area-under-curve (AUC) and half-life by 1.67-fold and by 1.56-fold, respectively. Alprazolam clearance was decreased by 60%.(8) In a double-blind cross-over study, concurrent ketoconazole decreased alprazolam clearance by 68.6% and increased alprazolam half-life by 2.9-fold.(9) Ketoconazole has also been shown to inhibit alprazolam metabolism in vitro.(10,11) In a double-blind, randomized cross-over study, itraconazole had no effects on the pharmacokinetics of a single dose of estazolam.(12) However, itraconazole was shown to inhibit the metabolism of estazolam in vitro(13) and the manufacturer of estazolam states that concurrent use with either itraconazole or ketoconazole is expected to increase estazolam levels and thus concurrent use is contraindicated.(2) In a study in 9 healthy subjects, itraconazole increased the AUC of oral midazolam by 8-fold. Increased effects were also noted.(14) In a double-blind cross-over study in 12 subjects, itraconazole increased the AUC, maximum concentration (Cmax) and half-life of oral midazolam by 6-fold, 2.5-fold, and 2-fold, respectively. Increased effects were also noted.(15) In a cross-over study in 12 subjects, one dose of itraconazole increased the AUC and Cmax of oral midazolam by 3.5-fold and by 2-fold, respectively. Six doses of itraconazole increased the AUC of oral midazolam by almost 7-fold. Increased midazolam effects were seen.(16) In a double-blind, cross-over study, itraconazole increased midazolam AUC by 10-fold. Subjects also experienced significantly increased sedation and amnesiac effects.(17) Itraconazole has also been shown to inhibit midazolam metabolism in vitro.(18,19) In a study in healthy subjects, ketoconazole increased the AUC of oral midazolam by 771.9%.(20) In a double-blind, cross-over study, ketoconazole increased midazolam AUC by 15-fold. Subjects also experienced significantly increased sedation and amnesiac effects.(17) In a study in 11 healthy subjects, administration of ketoconazole (400 mg daily) for 1 day, 2 days, and 5 days increased the AUC of a single dose of oral midazolam (2 mg) by 10.28-fold, 13.14-fold, and 13.96-fold, respectively, and the Cmax by 5.01-fold, 5.29-fold, and 5.42-fold, respectively.(21) In a study in healthy subjects, ketoconazole (200 mg twice daily) reduced the clearance of midazolam 6-fold.(22) Ketoconazole has also been shown to inhibit the metabolism of midazolam in vitro.(18,19,23-25) In a randomized, cross-over study in 10 healthy subjects, itraconazole ingested simultaneously, or 3, 12, or 24 hours before triazolam increased triazolam AUC by 3.1-fold, 4.8-fold, 4.6-fold, and 3.8-fold, respectively. The increased in triazolam Cmax ranged from 1.4-fold to 1.8-fold. Subjects noted increased triazolam effects.(23) In a double-blind cross-over study in 9 subjects, itraconazole increased triazolam AUC by 27-fold.(24) In a double-blind cross-over study in 9 subjects, ketoconazole increased triazolam AUC by 22-fold.(24) In a double-blind cross-over study, concurrent ketoconazole decreased triazolam clearance by 91%. Triazolam half-life and Cmax increased 5.1-fold and 1.1-fold, respectively.(9) Ketoconazole has also been shown to inhibit triazolam metabolism in vitro.(23,25) |
ITRACONAZOLE, ITRACONAZOLE MICRONIZED, KETOCONAZOLE, RECORLEV, SPORANOX, TOLSURA |
| Sodium Oxybate/Sedative Hypnotics; Alcohol SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Oxybate may be associated with respiratory depression. As oxybate is taken at bedtime, concurrent use with alcohol or hypnotics may increase the risk for respiratory depression or loss of consciousness.(1-3) Primidone is metabolized to phenobarbital. CLINICAL EFFECTS: Concurrent use of sodium oxybate and sedative hypnotics or alcohol may further increase the risk for respiratory depression and profound sedation or coma.(1,2) Fatalities have been reported.(3) PREDISPOSING FACTORS: Based upon FDA evaluation of deaths in patients taking sodium oxybate, risk factors may include: use of multiple drugs which depress the CNS, more rapid than recommended oxybate dose titration, exceeding the maximum recommended oxybate dose, and prescribing for unapproved uses such as fibromyalgia, insomnia or migraine. Note that in oxybate clinical trials for narcolepsy 78% - 85% of patients were also receiving concomitant CNS stimulants.(1-3) PATIENT MANAGEMENT: The FDA states that sodium oxybate is contraindicated in patients also taking hypnotics or alcohol.(1,2) Significant quantities of alcohol may be present in medicinal products. Alcohol is is used to improve docetaxel and paclitaxel solubility. - The quantity of alcohol in paclitaxel injection formulations (0.385-0.396 grams/mL) is similar across manufacturers. A paclitaxel 200 mg dose contains approximately 13 grams of alcohol. - The quantity of alcohol in docetaxel formulations varies approximately 3-fold depending upon the manufacturer. FDA data on alcohol content (4): Product Manufacturer Alcohol/200 mg dose Docetaxel Inj. Pfizer 6.4 grams Docetaxel Inj. Sandoz 5.5 grams Docetaxel Inj. Accord 4.0 grams Taxotere-one vial Sanofi 4.0 grams formulation Docetaxel Inj. Hospira 3.7 grams Docefrez Sun Pharma 2.9 grams Taxotere-two vial Sanofi 2.0 grams formulation DISCUSSION: The FDA evaluated sodium oxybate postmarket fatal adverse event reports from the FDA Adverse Event Reporting System(AERS)and from the manufacturer. Although report documentation was not always optimal or complete, useful information was obtained. Factors which may have contributed to fatal outcome: concomitant use of one or more drugs which depress the CNS, more rapid than recommended upward dose titration, exceeding the maximum recommended oxybate dose, and prescribing for unapproved uses such as fibromyalgia, insomnia or migraine. Many deaths occurred in patients with serious psychiatric disorders such as depression and substance abuse. Other concomitant diseases may have also contributed to respiratory and CNS depressant effects of oxybate.(3) |
LUMRYZ, LUMRYZ STARTER PACK, SODIUM OXYBATE, XYREM, XYWAV |
| Selected CYP3A4 Substrates/Mifepristone SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Mifepristone is an inhibitor of CYP3A4 and may increase levels and effects of drugs metabolized by this enzyme.(1) CLINICAL EFFECTS: Lovastatin, simvastatin and CYP3A4 substrates with a narrow therapeutic window such as alprazolam, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, and tacrolimus or CYP3A4 substrates with a high first pass effect such as oral midazolam, sildenafil, and triazolam are particularly susceptible to significant toxicity.(1,2) PREDISPOSING FACTORS: Due to the need for continuous therapy and mifepristone's long half-life of 85 hours(1) which leads to accumulation, patients with endogenous Cushing's syndrome may be at an increased risk for toxicity. With pimozide, the risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(3) PATIENT MANAGEMENT: The US manufacturer of mifepristone for hypercortisolism due to endogenous Cushing's syndrome states use with lovastatin, simvastatin, CYP3A4 substrates with a narrow therapeutic range, or CYP3A4 substrates with a high first pass effect is contraindicated.(1) DISCUSSION: Administration of mifepristone 1200 mg daily for 10 days followed by a single dose of simvastatin 80 mg led to an increase of simvastatin and simvastatin acid (active metabolite) area-under-curve (AUC) of 10.4-fold and 15.7-fold, respectively. |
KORLYM, MIFEPREX, MIFEPRISTONE |
| Alprazolam; Estazolam; Triazolam/Ribociclib SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Ribociclib may inhibit the metabolism of alprazolam, estazolam, and triazolam by CYP3A4.(1-4) CLINICAL EFFECTS: Inhibition of benzodiazepine metabolism may produce increased levels of these agents, as well as increased clinical effects, including profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of alprazolam,(1) estazolam,(2) or triazolam(3) with strong CYP3A4 inhibitors is contraindicated. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: In a study in healthy subjects, concomitant administration of ribociclib (400 mg once daily for 8 days) with midazolam increased the midazolam maximum concentration (Cmax) and area under the curve (AUC) by 2.1-fold and 3.8-fold, respectively. Administration of ribociclib 600 mg once daily is predicted to increase the midazolam Cmax and AUC by 2.4-fold and 5.2-fold, respectively.(4) |
KISQALI |
| Alprazolam; Triazolam/Selected Strong CYP3A4 Inhibitors SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Strong CYP3A4 inhibitors may inhibit the metabolism of alprazolam and triazolam.(1,2) CLINICAL EFFECTS: The concurrent administration of alprazolam or triazolam with strong CYP3A4 inhibitors may result in elevated levels of alprazolam or triazolam, which may result in increased adverse effects including profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturers of alprazolam and triazolam state that concurrent use with strong CYP3A4 inhibitors is contraindicated.(1,2) DISCUSSION: Many of the strong CYP3A4 inhibitors linked to this monograph have not been studied in combination with alprazolam or triazolam. However, other strong CYP3A4 have been well studied and are expected to cause a similar effect. In a study coadministration with ketoconazole increased alprazolam area-under-curve (AUC) by 3.98-fold.(1) In a study of 12 healthy volunteers, clarithromycin (500 mg twice daily for 2 days) increased the AUC of triazolam by 5-fold.(3) In a randomized, cross-over study in 10 healthy subjects, itraconazole ingested simultaneously, or 3, 12, or 24 hours before triazolam increased triazolam AUC by 3.1-fold, 4.8-fold, 4.6-fold, and 3.8-fold, respectively. The increase in triazolam Cmax ranged from 1.4-fold to 1.8-fold. Subjects noted increased triazolam effects.(4) In a double-blind cross-over study in 9 subjects, itraconazole increased triazolam AUC by 27-fold.(5) In a double-blind cross-over study in 9 subjects, ketoconazole increased triazolam AUC by 22-fold.(4) In a double-blind cross-over study, concurrent ketoconazole decreased triazolam clearance by 91%. Triazolam half-life and Cmax increased 5.1-fold and 1.1-fold, respectively.(6) Serum concentrations and the half-life of triazolam were increased by troleandomycin by as much as 258%.(7) Strong CYP3A4 inhibitors linked to this monograph include: adagrasib, boceprevir, ceritinib, clarithromycin, cobicistat, grapefruit, idelalisib, josamycin, lonafarnib, mibefradil, posaconazole, telaprevir, telithromycin, troleandomycin, tucatinib, and voriconazole.(8) |
CLARITHROMYCIN, CLARITHROMYCIN ER, GENVOYA, KRAZATI, LANSOPRAZOL-AMOXICIL-CLARITHRO, NOXAFIL, OMECLAMOX-PAK, POSACONAZOLE, PREZCOBIX, STRIBILD, SYMTUZA, TUKYSA, TYBOST, VFEND, VFEND IV, VOQUEZNA TRIPLE PAK, VORICONAZOLE, ZOKINVY, ZYDELIG, ZYKADIA |
There are 8 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Clozapine/Benzodiazepines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The exact mechanism is unknown. Some benzodiazepines may increase clozapine levels.(1) CLINICAL EFFECTS: Concurrent administration of clozapine with a benzodiazepine may result in orthostatic hypotension, delirium, collapse, profound sedation, respiratory arrest, and/or cardiac arrest.(2-3) PREDISPOSING FACTORS: Patients with preexisting cardiovascular, liver, organic brain disease(1) or sleep apnea may be predisposed to the interaction. The interaction may be more likely when initiating clozapine therapy, when restarting clozapine after a brief clozapine-free interval, or when adding clozapine to benzodiazepine therapy.(1,2) PATIENT MANAGEMENT: The concurrent use of clozapine with benzodiazepines should be approached with caution, especially in patients who have recently started or restarted clozapine therapy. Monitor patients for excessive sedation, decreased respiratory rate, and ataxia.(3) DISCUSSION: Collapse has been reported in a patients in whom clozapine and clonazepam were initiated simultaneously.(4) Somnolence, confusion, ataxia, and disorientation were reported in a patient following the addition of clozapine to clonazepam therapy.(5) Collapse has been reported in three patients maintained on diazepam in whom clozapine was initiated.(6,7) Cardiac arrest and death during sleep were reported in a patient in whom clozapine and oxazepam were initiated simultaneously.(4) Delirium has been reported in four clozapine-treated patients in whom lorazepam was initiated.(5,8) Respiratory arrest and death were reported in one patient in whom clozapine was initiated who had been maintained on oral lorazepam. The patient received three supplemental doses of intravenous lorazepam for increased psychosis and was found dead 12 hours later.(9) |
CLOZAPINE, CLOZAPINE ODT, CLOZARIL, VERSACLOZ |
| Ethyl Alcohol/Benzodiazepines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use may result in additive central nervous system depressant effects. Concurrent use may also result in altered absorption, altered distribution, or decreased elimination leading to higher concentrations of the benzodiazepine in the brain.(1-4) CLINICAL EFFECTS: Concurrent use of benzodiazepines and alcohol-containing products may result in enhanced disruption of psychomotor performance and increased central nervous system depression. Increased CNS depression may result in profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should be informed that alcohol consumption may result in significant decreased psychomotor performance and its associated risks. Use of a short acting benzodiazepine may minimize the potential for extreme effects. If suicide or drug abuse is a concern, benzodiazepine use may be ill advised, since alcohol tends to greatly increase benzodiazepine-induced CNS depression in acute overdosage. Patients should be informed about unsuspected sources of alcohol such as medications. Alcohol is used to improve docetaxel and paclitaxel solubility. - The quantity of alcohol in paclitaxel injection formulations (0.385-0.396 grams/mL) is similar across manufacturers. A paclitaxel 200 mg dose contains approximately 13 grams of alcohol. - The quantity of alcohol in docetaxel formulations varies approximately 3-fold depending upon the manufacturer. FDA data on alcohol content (18): Product Manufacturer Alcohol/200 mg dose Docetaxel Inj. Pfizer 6.4 grams Docetaxel Inj. Sandoz 5.5 grams Docetaxel Inj. Accord 4.0 grams Taxotere-one vial Sanofi 4.0 grams formulation Docetaxel Inj. Hospira 3.7 grams Docefrez Sun Pharma 2.9 grams Taxotere-two vial Sanofi 2.0 grams formulation DISCUSSION: Several articles have detailed enhanced disruption of psychomotor performance and increased CNS depression with concurrent use of diazepam and alcohol.(1-6) Evidence shows that temazepam and the other short-acting or intermediate-acting benzodiazepines (e.g., alprazolam, halazepam, triazolam) tend to result in less profound alcohol interactions.(7) Although one study showed no effect on triazolam pharmacokinetics, a clinically significant pharmacodynamic interaction cannot be ruled out.(8) Other reports have shown clinically significant effects from concurrent triazolam and alcohol use.(9,10) In 8 healthy subjects, concurrent midazolam and alcohol resulted in impairment of immediate recall.(11) In a similar study, the hypnotic effect of midazolam was augmented by alcohol.(12) In a study involving 9 subjects, measurements of total reaction time were longer after concurrent alcohol and lorazepam as compared to the use of either agent alone.(13) Reports have been conflicting regarding the actions of chlordiazepoxide when combined with alcohol. Differences in time of exposure, dosage, and response parameters have been used to explain the inconsistent findings with chlordiazepoxide.(14) |
ALCOHOL,DEHYDRATED |
| Midazolam; Triazolam/Diltiazem; Verapamil SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Diltiazem and verapamil may inhibit the metabolism of midazolam and triazolam by CYP3A4.(1-7) CLINICAL EFFECTS: Concurrent use of diltiazem or verapamil may result in elevated levels of and clinical effects, including profound sedation, respiratory depression, coma, and/or death, from midazolam and triazolam.(1-4) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Consider the use of alternative agents to midazolam and triazolam in patients maintained on diltiazem or verapamil. The concurrent use of midazolam or triazolam with diltiazem or verapamil should be approached with caution. The dose of midazolam or triazolam should be reduced and patients should be observed for increased benzodiazepine effects such as prolonged sedation.(1-4) If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: In a double-blind, randomized, cross-over study in 9 healthy subjects, pretreatment with diltiazem (60 mg 3 times daily for 2 days) increased the area-under-curve (AUC) of a single oral dose of midazolam (15 mg) by 2.75-fold. Midazolam maximum concentration (Cmax) doubled and half-life (T1/2) was prolonged. These changes were associated with profound and prolonged sedative effects.(1) In a double-blind, randomized, cross-over study in 9 healthy subjects, pretreatment with verapamil (80 mg 3 times daily for 2 days) increased the AUC of a single oral dose of midazolam (15 mg) by 1.9-fold. Midazolam Cmax doubled and T1/2 was prolonged. These changes were associated with profound and prolonged sedative effects.(1) In a randomized, cross-over study in 7 healthy males, pretreatment with diltiazem (180 mg daily for 3 days) increased the AUC, Cmax, and T1/s of a single oral dose of triazolam (0.25 mg) by 1.275-fold, 71%, and 85%, respectively. Pharmacodynamic effects of triazolam were significantly increased as measured by peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS).(2) In a randomized, double-blind, cross-over study in 10 healthy subjects, pretreatment with diltiazem (60 mg 3 times daily for 2 days) increased the AUC, Cmax, and T1/2 of a single oral dose of triazolam (0.25 mg) by 3-fold, 2-fold, and 2-fold, respectively. These changes were associated with increased and prolonged pharmacodynamic effects.(3) Studies have shown that diltiazem increases midazolam and triazolam AUC by 3-fold to 4-fold, Cmax by 2-fold, and T1/2 by 1.5-fold to 2.5-fold.(4) |
CARDIZEM, CARDIZEM CD, CARDIZEM LA, CARTIA XT, DILT-XR, DILTIAZEM 12HR ER, DILTIAZEM 24HR ER, DILTIAZEM 24HR ER (CD), DILTIAZEM 24HR ER (LA), DILTIAZEM 24HR ER (XR), DILTIAZEM HCL, DILTIAZEM HCL-0.7% NACL, DILTIAZEM HCL-0.9% NACL, DILTIAZEM HCL-NACL, DILTIAZEM-D5W, MATZIM LA, TIADYLT ER, TIAZAC, TRANDOLAPRIL-VERAPAMIL ER, VERAPAMIL ER, VERAPAMIL ER PM, VERAPAMIL HCL, VERAPAMIL SR |
| Alprazolam; Estazolam; Midazolam; Triazolam/Nefazodone SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Nefazodone is a strong inhibitor of CYP3A4 and may decrease metabolism of benzodiazepines cleared by this pathway. CLINICAL EFFECTS: Concurrent administration of nefazodone and benzodiazepines metabolized by CYP3A4 may result in increased clinical effects of benzodiazepines, including toxic effects profound sedation, respiratory depression, coma, and/or death. CYP3A4 is the major or only hepatic metabolism pathway for the phase I elimination of alprazolam, estazolam, midazolam, and triazolam. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Benzodiazepines that do not undergo extensive CYP hepatic metabolism (e.g. lorazepam, oxazepam) may be an alternative in nefazodone patients. If nefazodone is administered in combination with triazolam, the manufacturer of nefazodone recommends that the initial dose triazolam be reduced by 75%. In interaction studies nefazodone 200 mg twice daily increased triazolam exposure (area-under-curve, AUC) 4-fold. However, because not all commercially available triazolam dosage forms permit a sufficient dosage adjustment, the manufacturer of nefazodone recommends that the combination of nefazodone and triazolam be avoided in most patients, especially the elderly. When nefazodone is coadministered with alprazolam, AUC and half-life increased approximately 2-fold. The US manufacturers of nefazodone recommend a 50% reduction in the initial dose of alprazolam. The US manufacturer of estazolam recommends caution and consideration of an appropriate dose reduction when concomitant therapy is considered. Two other strong CYP3A4 inhibitors, itraconazole and oral ketoconazole, are contraindicated with estazolam use. It would be prudent to avoid the combination of nefazodone and estazolam. If nefazodone is started in a patient already receiving a benzodiazepine primarily metabolized by CYP3A4, then monitor closely and anticipate the need to reduce the benzodiazepine dose. Counsel patient to report excess drowsiness, confusion, memory problems including sleep-driving behaviors, loss of coordination, slowed or difficult breathing, or unresponsiveness. DISCUSSION: In an interaction study, nefazodone 200 mg twice daily increased triazolam exposure (area-under-curve, AUC) 4-fold. When nefazodone is coadministered with alprazolam, AUC and half-life increased approximately 2-fold. |
NEFAZODONE HCL |
| Opioids (Cough and Cold)/Benzodiazepines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of opioids and benzodiazepines may result in additive CNS depression.(1) CLINICAL EFFECTS: Concurrent use of opioids and other CNS depressants, such as benzodiazepines, may result in profound sedation, respiratory depression, coma, and/or death.(1) PREDISPOSING FACTORS: Concurrent use of alcohol or other CNS depressants may increase the risk of adverse effects. PATIENT MANAGEMENT: Avoid prescribing opioid-including cough medications for patients taking CNS depressants such as benzodiazepines.(1) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(2) If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(1) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(3) DISCUSSION: Between 2002 and 2014, the number of patients receiving an opioid analgesic increased 8%, from 75 million to 81 million patients, and the number of patients receiving a benzodiazepine increased 31%, from 23 million to 30 million patients. During this time, the proportion of patients receiving concurrent therapy increased 31%, from 23 million to 30 million patients.(4) From 2004 to 2011, the rate of nonmedical use-related emergency room visits involving both opioids and benzodiazepines increased from 11 to 34.2 per 100,000 and drug overdose deaths involving both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000. The proportion of prescription opioid analgesic deaths which also involved benzodiazepines increased from 18% to 31% during this time.(5) A prospective observational cohort study in North Carolina found that the rates of overdose death among patients co-dispensed opioid analgesics and benzodiazepines were 10 times higher than patients receiving opioid analgesics alone.(6) A case-cohort study of VA data from 2004-2009 found that the risk of death from overdose increased with concomitant opioid analgesics and benzodiazepines. Compared to patients with no history of benzodiazepines, patients with a history of benzodiazepine use (hazard ratio [HR] = 2.33) and patients with a current benzodiazepine prescription (HR=3.86) had an increased risk of fatal overdose.(7) A study found that opioid analgesics contributed to 77% of deaths in which benzodiazepines were determined to be a cause of death and that benzodiazepines contributed to 30% of deaths in which opioid analgesics were determined to be a cause of death. This study also found that other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) were contributory to death in many cases where opioid analgesics were also implicated.(8) A study found that alcohol was involved in 18.5% of opioid analgesic abuse-related ED visits and 22.1 percent of opioid analgesic-related deaths.(9) A study of 315,428 privately insured patients who filled at least one prescription for an opioid from 2001 to 2013 were enrolled in a retrospective study. Concurrent use of a benzodiazepine was recorded as having at least one day of overlap in a given calendar year. Baseline characteristics among opioid users with concurrent use of a benzodiazepine were older (44.5 v. 42.4, p<0.001), less likely to be men (35% v. 43%, p<0.001), and had a higher prevalence rate of every comorbidity examined (p<0.001). The proportion of opioid users with concurrent benzodiazepine use nearly doubled from 9% in 2001 to 17% in 2013. The primary outcome was an emergency room visit or inpatient admission for opioid overdose within a calendar year. Among all opioid users, the annual adjusted incidence for the primary outcome was 1.16% without concurrent benzodiazepine use compared to 2.42% with concurrent benzodiazepine use (OR 2.14; 95% CI 2.05-2.24; p<0.001). Intermittent opioid users (1.45% v. 1.02%; OR 1.42; 95% CI 1.33-1.51; p<0.001) and chronic opioid users (5.36% v. 3.13%; OR 1.81; 95% CI 1.67-1.96; p<0.001) also experienced a higher adjusted incidence of the primary outcome with concurrent benzodiazepine use compared to without concurrent benzodiazepine use, respectively.(10) In a nested case-control study of adults with a new opioid dispensing between 2010-2018, patients with concurrent use of an opioid with a benzodiazepine were significantly more likely to have opioid-related overdose compared to patients receiving opioids, benzodiazepines, or neither (OR 9.28; 95% CI 7.87, 10.93). Longer concurrent use of 1-7, 8-30, and 31-90 days was associated with 4.6, 12.1, and 26.7-fold higher likelihood of opioid-related overdose (p<0.01). Patients with overlapping prescriptions during previous 0-30, 31-60, and 61-90 days were 13.2, 6.0, and 3.2-times more likely to experience an overdose (p<0.01).(11) |
HYCODAN, HYDROCODONE-CHLORPHENIRAMNE ER, HYDROCODONE-HOMATROPINE MBR, HYDROMET, PROMETHAZINE-CODEINE, TUXARIN ER |
| Selected Sensitive CYP3A4 Substrates/Oral Lefamulin SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Lefamulin is considered a moderate inhibitor of CYP3A4. FDA defines a moderate inhibitor as a drug which increases the area-under-curve (AUC) of a sensitive substrate by 2- to 5-fold.(1,4) CLINICAL EFFECTS: Concurrent use of oral lefamulin may lead to increased serum levels and adverse effects of drugs sensitive to inhibition of the CYP3A4 pathway.(1) PREDISPOSING FACTORS: With darifenacin, the risk of anticholinergic toxicities including cognitive decline, delirium, falls and fractures is increased in geriatric patients using more than one medicine with anticholinergic properties.(5) PATIENT MANAGEMENT: If oral lefamulin must be coadministered with a sensitive CYP3A4 substrate, it is recommended to closely monitor for adverse effects of the CYP3A4 substrate.(1) Drug-specific recommendations: The manufacturer of abemaciclib recommends monitoring for adverse reactions and considering a dose reduction of abemaciclib in 50 mg decrements as detailed in prescribing information (based on starting dose, previous dose reductions, and combination or monotherapy use) with concurrent use of moderate CYP3A4 inhibitors.(2) The US manufacturer of sirolimus protein-bound injection (Fyarro) states a dose reduction to 56 mg/m2 is recommended when used concurrently with moderate or weak CYP3A4 inhibitors. Concurrent use with strong CYP3A4 inhibitors should be avoided.(3) DISCUSSION: In a study, oral lefamulin tablets administered concomitantly with and at 2 or 4 hours before oral midazolam (a CYP3A4 substrate) increased the area-under-curve (AUC) and maximum concentration (Cmax) of midazolam by 200% and 100%, respectively. No clinically significant effect on midazolam pharmacokinetics was observed when co-administered with lefamulin injection.(1) Sensitive CYP3A4 substrates linked to this monograph include: abemaciclib, acalabrutinib, alfentanil, alprazolam, atorvastatin, brotizolam, budesonide, buspirone, cobimetinib, darifenacin, ebastine, eletriptan, elvitegravir, everolimus, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, paritaprevir, sildenafil, simvastatin, sirolimus, ticagrelor, triazolam, and ulipristal.(1,4,6) |
XENLETA |
| Selected CYP3A4 Substrates/Pexidartinib SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Pexidartinib is a moderate inducer of CYP3A4 and may increase the metabolism of drugs metabolized by the CYP3A4 enzyme. CLINICAL EFFECTS: Concurrent use of pexidartinib may lead to decreased serum levels and effectiveness of drugs metabolized by the CYP3A4 pathway.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of pexidartinib states that co-administration of CYP3A4 substrates for which minimal concentration decreases may lead to serious therapeutic failure should be avoided. If concomitant use is unavoidable, increase the dose of the CYP3A4 substrate in accordance with approved product labeling.(1) DISCUSSION: Coadministration of pexidartinib 400 mg twice daily with oral midazolam, a sensitive CYP3A4 substrate, in patients decreased midazolam area-under-curve (AUC) by 59% and maximum concentration (Cmax) by 28%.(1) CYP3A4 substrates with a narrow therapeutic index linked to this monograph include: alfentanil, everolimus, felodipine, fentanyl, hydroquinidine, midazolam, nisoldipine, quinidine, sirolimus, tacrolimus, ticagrelor, and triazolam.(1-3) |
TURALIO |
| Selected CYP3A4 Substrates/Sotorasib SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sotorasib is a moderate inducer of CYP3A4 and may increase the metabolism of drugs metabolized by the CYP3A4 enzyme. CLINICAL EFFECTS: Concurrent use of sotorasib may lead to decreased serum levels and effectiveness of drugs metabolized by the CYP3A4 pathway.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of sotorasib states that co-administration of CYP3A4 substrates for which minimal concentration decreases may lead to serious therapeutic failure should be avoided. If concomitant use is unavoidable, increase the dose of the CYP3A4 substrate in accordance with approved product labeling.(1) DISCUSSION: Coadministration of sotorasib with midazolam, a sensitive CYP3A4 substrate, decreased midazolam area-under-curve (AUC) by 53% and maximum concentration (Cmax) by 48%.(1) CYP3A4 substrates with a narrow therapeutic index linked to this monograph include: alfentanil, felodipine, fentanyl, hydroquinidine, parenteral lefamulin, midazolam, nisoldipine, quinidine, tacrolimus, ticagrelor, and triazolam.(2,3) |
LUMAKRAS |
There are 13 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Cimetidine/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Cimetidine may decrease the metabolism of Phase I hepatically metabolized benzodiazepines. At doses of 800-2400 mg daily, cimetidine is a weak inhibitor of CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4. CLINICAL EFFECTS: Concurrent use may result in increased pharmacologic or toxic effects of certain benzodiazepines. Toxic effects include profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Benzodiazepines that do not undergo extensive Phase I metabolism (lorazepam, oxazepam) may be an alternative to interacting benzodiazepines in patients receiving cimetidine or by administering another H-2 antagonist (e.g., ranitidine, famotidine, nizatidine). Cimetidine use at higher doses of 200-400 mg four times daily would have an increased risk of inhibiting the metabolism of benzodiazepines. Lower doses and over-the-counter doses of cimetidine would be expected to have a diminished effect. Consider using alternative H2 antagonists when long-term concurrent therapy with benzodiazepines is indicated. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Cimetidine increases the half-life and serum concentration and decreases the clearance of benzodiazepines that undergo oxidative metabolism (e.g., alprazolam, bromazepam, diazepam, flurazepam, midazolam, triazolam). In a clinical study, cimetidine 1,200 mg daily decreased the clearance of bromazepam by 50% and increased its half-life from 23 hours to 29 hours.(22) The sedative effects of benzodiazepines have been reported to be increased during concurrent administration of cimetidine. This interaction does not appear to occur with benzodiazepines that undergo glucuronide conjugation. |
CIMETIDINE |
| Selected Oral Benzodiazepines/Aprepitant (Greater Than 40 mg); Netupitant SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Netupitant and aprepitant doses greater than 40 mg per day are classified as moderate inhibitors of CYP3A4 and may inhibit the CYP3A4 mediated absorption and metabolism of midazolam or triazolam.(1-4) CLINICAL EFFECTS: Concurrent administration of aprepitant or netupitant may result in increased levels of and effects from the benzodiazepines.(1-4) Toxic effects of increased levels of benzodiazepines include profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Depending on patient tolerance, the benzodiazepine dosage may need to be reduced or an alternative agent not metabolized by CYP3A4 (e.g. lorazepam, temazepam) may be used. Patients receiving concurrent therapy with aprepitant or netupitant and midazolam or triazolam should be closely monitored and counseled regarding possible adverse effects due to increased benzodiazepine exposure. Due to its long half-life, the effects of a single dose of netupitant persist for 4 or more days. DISCUSSION: In an open-label, randomized single-period study in 16 healthy subjects, administration of aprepitant (125 mg on Day 1, 80 mg on Days 2-5) increased the area-under-curve (AUC) of a single oral dose of midazolam (2 mg on Day 1 and Day 5) by 2.3-fold on Day 1 and by 3.3-fold on Day 5 when compared to midazolam alone. Midazolam maximum concentration (Cmax) increased by 1.5-fold on Day 1 and by 1.9-fold on Day 5.(1,5) Midazolam half-life increased from 1.7 hours for midazolam alone to 3.3 hours on Day 1 and Day 5. In the second group, administration of aprepitant (40 mg on Day 1, 25 mg on Days 2-5) with midazolam had no significant effects on midazolam AUC, Cmax, or half-life.(6) In a study, administration of a single dose of aprepitant (40 mg) increased the AUC of a single dose of oral midazolam (2 mg) by 1.2-fold. This was not considered clinically significant.(1) In a study in 12 healthy subjects, administration of aprepitant (125 mg on Day 1, 80 mg on Days 2-3) increased the AUC of a single dose of intravenous midazolam (2 mg on Days 4, 8, and 15) by 25% on Day 4. The AUC of midazolam was decreased by 19% on Day 8. These effects were not considered clinically significant.(1,5) In a study, administration of a single dose of intravenous midazolam (2 mg) 1 hour after a single dose of aprepitant (125 mg) increased midazolam AUC by 1.5-fold.(1) In a study, co-administration of a single dose of netupitant 300 mg and oral midazolam 7.5 mg led to an increase in the Cmax and AUC of midazolam by 36% and 126% respectively.(4) |
AKYNZEO, APREPITANT, CINVANTI, EMEND |
| Selected Benzodiazepines/Selected CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: CYP3A4 inducers may induce the metabolism of some benzodiazepines. CLINICAL EFFECTS: Concurrent or recent use of CYP3A4 inducers may result in decreased levels and loss of effectiveness of some benzodiazepines. PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Monitor patients receiving CYP3A4 inducers or who have received these agents in the previous 2 weeks for decreased benzodiazepine effectiveness. The dose of the benzodiazepine may need to be adjusted or an alternative agent used. If the CYP3A4 inducer is discontinued, benzodiazepine levels will gradually rise as induction effects diminish. Monitor for increased benzodiazepine effects and adjust the dose accordingly. DISCUSSION: In a study in 95 healthy subjects, rifampin (450 mg daily for 5 days) decreased the plasma concentrations of a single oral dose of alprazolam (1 mg) by 79%.(1) In another study in 4 healthy subjects, rifampin (given for 4 days) decreased the area-under-curve (AUC) of a single oral dose of alprazolam (1 mg) by 88%.(2) In a double-blind, randomized, cross-over trial in 13 healthy subjects, rifampin (450 mg daily for 7 days) decreased the maximum concentration (Cmax), AUC, and half-life of a single oral dose of brotizolam (0.5 mg) by 69%, 90%, and 69%, respectively. Concurrent rifampin increased scores on the Digit Symbol Substitution Test (DSST) and decreased scores on the Stanford Sleepiness Scale.(3) In a study in 21 healthy subjects, rifampin (600 mg or 1200 mg daily for 7 days) increased total body clearance of diazepam by 300%.(4) An in vitro study in human hepatocytes found that rifampin increased the biotransformation of diazepam and midazolam by 1.9-fold.(5) In a study in 24 healthy subjects, rifampin (600 mg daily for 10 days) increased the clearance of a single intravenous dose of lorazepam by 140%.(6) In an open-label cross-over study in 19 healthy subjects, rifampin (600 mg daily for 9 days) increased the clearance of a single oral dose of midazolam (0.075 mg/kg) by 7-fold.(7) In a study in 57 healthy subjects, rifampin increased the systemic and oral clearance of midazolam by 2-fold and 16-fold, respectively.(8) In a study in 8 healthy subjects, rifampin (given for 6 days) significantly increased the clearance of midazolam.(9) In a study in 9 healthy subjects, received a single oral dose of midazolam (15 mg) before, one day after the administration of rifampin (600 mg daily for 5 days), and 4 days after the last dose of rifampin. One day after rifampin, the AUC of midazolam was decreased by 97.7% when compared to the administration of midazolam prior to rifampin. Four days after the completion of rifampin, the AUC of midazolam was decreased by 87% when compared to the administration of midazolam prior to rifampin.(10) In a double-blind, randomized, cross-over study in 10 healthy subjects, rifampin (600 mg daily for 5 days) decreased the Cmax, AUC, and half-life of a single oral dose of midazolam (15 mg) by 94%, 96%, and 58%, respectively. The pharmacodynamic effects of midazolam were also significantly decreased during rifampin therapy.(11) In a study in 16 healthy subjects, rifampin (600 mg daily for 7 days) increased the clearance of nitrazepam by 83%. There were no significant effects on the pharmacokinetics of temazepam.(12) In a randomized, double-blind, cross-over study in 10 healthy subjects, rifampin (600 mg daily for 5 days) decreased the Cmax, AUC, and half-life of a single dose of triazolam (0.5 mg) by 87.6%, 94.9%, and 54%, respectively. The pharmacodynamic effects of triazolam were also significantly decreased during rifampin therapy.(13) In an open-label, randomized, cross-over study in 27 healthy subjects, rifaximin (200 mg three times daily for 7 days) had no effect on the pharmacokinetics of single doses of oral or intravenous midazolam.(14) In a study in 98 patients with schizophrenia or bipolar disorder, the expression of CYP3A4 was found to be the major determinant of clonazepam plasma concentrations normalized by the dose and bodyweight (1263 +/- 482.9 and 558.5 +/- 202.4 ng/mL per mg/kg bodyweight in low and normal expressers, respectively, p<0.0001).(18) Selected CYP3A4 inducers linked to this monograph include: apalutamide, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenytoin, rifabutin, rifampin, rifapentine, and St. John's wort. |
BRAFTOVI, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, DILANTIN, DILANTIN-125, EPITOL, EQUETRO, ERLEADA, FOSPHENYTOIN SODIUM, LYSODREN, MITOTANE, ORKAMBI, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PRIFTIN, RIFABUTIN, RIFADIN, RIFAMPIN, TALICIA, TEGRETOL, TEGRETOL XR, TIBSOVO, XTANDI |
| Buprenorphine/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Buprenorphine is a partial agonist at mu-opioid receptors leading to ceiling effects which limit agonist activity, including respiratory depression, at high doses. However, concomitant benzodiazepine use (e.g. taken shortly after buprenorphine dose) or high doses of benzodiazepines may lead to potentiation of respiratory depression, counteracting the ceiling effect.(1,2) Concurrent use of buprenorphine and benzodiazepines may result in additive CNS depression.(3) CLINICAL EFFECTS: Concurrent use may result in profound sedation, respiratory depression, coma, and/or death. Fatal respiratory depression has occurred with the combination of buprenorphine and a benzodiazepine.(1-2,4-7) High benzodiazepine levels have been identified in 80% or more of buprenorphine fatalities.(6) PREDISPOSING FACTORS: Patients with a history of alcohol or benzodiazepine abuse may be at risk for relapse and overuse or abuse of prescribed benzodiazepines.(1,2,4,6) Individuals with significant obstructive pulmonary disease (COPD), sleep apnea, the elderly, and debilitated patients are at greater risk for respiratory depression from either agent.(1,2,8) PATIENT MANAGEMENT: Limit prescribing opioid analgesics with CNS depressants such as benzodiazepines to patients for whom alternatives are inadequate.(3) For buprenorphine patients newly starting a benzodiazepine, consider beginning the benzodiazepine at a lower than usual dose, especially if predisposing factors (e.g. COPD, sleep apnea, debilitation, elderly) are present. High doses of benzodiazepines are associated with a greater risk for respiratory depression. Use the lowest effective dose and monitor for excessive sedation or respiratory depression, particularly in patients with predisposing risk factors for respiratory compromise.(1,2) Buprenorphine-naloxone combination products are used for maintenance treatment of opioid dependence. Patients with comorbid benzodiazepine dependence, on high doses of benzodiazepines, or a history of benzodiazepine abuse may require benzodiazepine detoxification prior to initiation of office-based buprenorphine treatment.(3) For patients receiving opioid maintenance treatment, it would be prudent to assure all controlled substance prescriptions are approved or written by the buprenorphine-naloxone provider.(5) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(9) Monitor patients receiving concurrent therapy for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(3) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(10) DISCUSSION: Buprenorphine is a partial agonist at mu-opioid receptors leading to ceiling effects which limits agonist activity, including respiratory depression, at high doses. However, concomitant benzodiazepine use (e.g. taking shortly after buprenorphine dose) or high doses of benzodiazepines may counteract the ceiling effect leading to potentiation of respiratory depression or sedative effects. High benzodiazepine levels have identified in 80% or more of buprenorphine fatalities.(6) Between 2002 and 2014, the number of patients receiving an opioid analgesic increased 8%, from 75 million to 81 million patients, and the number of patients receiving a benzodiazepine increased 31%, from 23 million to 30 million patients. During this time, the proportion of patients receiving concurrent therapy increased 31%, from 23 million to 30 million patients.(11) From 2004 to 2011, the rate of nonmedical use-related emergency room visits involving both opioids and benzodiazepines increased from 11 to 34.2 per 100,000 and drug overdose deaths involving both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000. The proportion of prescription opioid analgesic deaths which also involved benzodiazepines increased from 18% to 31% during this time.(12) A prospective observational cohort study in North Carolina found that the rates of overdose death among patients co-dispensed opioid analgesics and benzodiazepines were 10 times higher than patients receiving opioid analgesics alone.(13) A case-cohort study of VA data from 2004-2009 found that the risk of death from overdose increased with concomitant opioid analgesics and benzodiazepines. Compared to patients with no history of benzodiazepines, patients with a history of benzodiazepine use (hazard ratio [HR] = 2.33) and patients with a current benzodiazepine prescription (HR=3.86) had an increased risk of fatal overdose.(14) A study found that opioid analgesics contributed to 77% of deaths in which benzodiazepines were determined to be a cause of death and that benzodiazepines contributed to 30% of deaths in which opioid analgesics were determined to be a cause of death. This study also found that other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) were contributory to death in many cases where opioid analgesics were also implicated.(15) A study found that alcohol was involved in 18.5% of opioid analgesic abuse-related ED visits and 22.1 percent of opioid analgesic-related deaths.(16) A study of 315,428 privately insured patients who filled at least one prescription for an opioid from 2001 to 2013 were enrolled in a retrospective study. Concurrent use of a benzodiazepine was recorded as having at least one day of overlap in a given calendar year. Baseline characteristics among opioid users with concurrent use of a benzodiazepine were older (44.5 v. 42.4, p<0.001), less likely to be men (35% v. 43%, p<0.001), and had a higher prevalence rate of every comorbidity examined (p<0.001). The proportion of opioid users with concurrent benzodiazepine use nearly doubled from 9% in 2001 to 17% in 2013. The primary outcome was an emergency room visit or inpatient admission for opioid overdose within a calendar year. Among all opioid users, the annual adjusted incidence for the primary outcome was 1.16% without concurrent benzodiazepine use compared to 2.42% with concurrent benzodiazepine use (OR 2.14; 95% CI 2.05-2.24; p<0.001). Intermittent opioid users (1.45% v. 1.02%; OR 1.42; 95% CI 1.33-1.51; p<0.001) and chronic opioid users (5.36% v. 3.13%; OR 1.81; 95% CI 1.67-1.96; p<0.001) also experienced a higher adjusted incidence of the primary outcome with concurrent benzodiazepine use compared to without concurrent benzodiazepine use, respectively.(17) |
BELBUCA, BRIXADI, BUPRENORPHINE, BUPRENORPHINE HCL, BUPRENORPHINE-NALOXONE, BUTRANS, SUBLOCADE, SUBOXONE, ZUBSOLV |
| Opioids (Extended Release)/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use of opioids and benzodiazepines may result in additive CNS depression.(1) CLINICAL EFFECTS: Concurrent use of opioids and other CNS depressants, such as benzodiazepines, may result in profound sedation, respiratory depression, coma, and/or death.(1) PREDISPOSING FACTORS: Concurrent use of alcohol or other CNS depressants may increase the risk of adverse effects. PATIENT MANAGEMENT: Limit prescribing opioid analgesics with CNS depressants such as benzodiazepines to patients for whom alternatives are inadequate.(1) If concurrent use is necessary, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. If starting a CNS depressant (for an indication other than epilepsy) with an opioid analgesic, prescribe a lower initial dose of the CNS depressant than indicated in the absence of an opioid and titrate based upon clinical response. If an opioid analgesic is indicated in a patient already taking a CNS depressant, prescribe a lower dose of the opioid and titrate based upon clinical response.(1) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(2) Monitor patients receiving concurrent therapy for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(1) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(3) DISCUSSION: Between 2002 and 2014, the number of patients receiving an opioid analgesic increased 8%, from 75 million to 81 million patients, and the number of patients receiving a benzodiazepine increased 31%, from 23 million to 30 million patients. During this time, the proportion of patients receiving concurrent therapy increased 31%, from 23 million to 30 million patients.(4) From 2004 to 2011, the rate of nonmedical use-related emergency room visits involving both opioids and benzodiazepines increased from 11 to 34.2 per 100,000 and drug overdose deaths involving both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000. The proportion of prescription opioid analgesic deaths which also involved benzodiazepines increased from 18% to 31% during this time.(5) A prospective observational cohort study in North Carolina found that the rates of overdose death among patients co-dispensed opioid analgesics and benzodiazepines were 10 times higher than patients receiving opioid analgesics alone.(6) A case-cohort study of VA data from 2004-2009 found that the risk of death from overdose increased with concomitant opioid analgesics and benzodiazepines. Compared to patients with no history of benzodiazepines, patients with a history of benzodiazepine use (hazard ratio [HR] = 2.33) and patients with a current benzodiazepine prescription (HR=3.86) had an increased risk of fatal overdose.(7) A study found that opioid analgesics contributed to 77% of deaths in which benzodiazepines were determined to be a cause of death and that benzodiazepines contributed to 30% of deaths in which opioid analgesics were determined to be a cause of death. This study also found that other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) were contributory to death in many cases where opioid analgesics were also implicated.(8) A study found that alcohol was involved in 18.5% of opioid analgesic abuse-related ED visits and 22.1 percent of opioid analgesic-related deaths.(9) A study of 315,428 privately insured patients who filled at least one prescription for an opioid from 2001 to 2013 were enrolled in a retrospective study. Concurrent use of a benzodiazepine was recorded as having at least one day of overlap in a given calendar year. Baseline characteristics among opioid users with concurrent use of a benzodiazepine were older (44.5 v. 42.4, p<0.001), less likely to be men (35% v. 43%, p<0.001), and had a higher prevalence rate of every comorbidity examined (p<0.001). The proportion of opioid users with concurrent benzodiazepine use nearly doubled from 9% in 2001 to 17% in 2013. The primary outcome was an emergency room visit or inpatient admission for opioid overdose within a calendar year. Among all opioid users, the annual adjusted incidence for the primary outcome was 1.16% without concurrent benzodiazepine use compared to 2.42% with concurrent benzodiazepine use (OR 2.14; 95% CI 2.05-2.24; p<0.001). Intermittent opioid users (1.45% v. 1.02%; OR 1.42; 95% CI 1.33-1.51; p<0.001) and chronic opioid users (5.36% v. 3.13%; OR 1.81; 95% CI 1.67-1.96; p<0.001) also experienced a higher adjusted incidence of the primary outcome with concurrent benzodiazepine use compared to without concurrent benzodiazepine use, respectively.(10) In a nested case-control study of adults with a new opioid dispensing between 2010-2018, patients with concurrent use of an opioid with a benzodiazepine were significantly more likely to have opioid-related overdose compared to patients receiving opioids, benzodiazepines, or neither (OR 9.28; 95% CI 7.87, 10.93). Longer concurrent use of 1-7, 8-30, and 31-90 days was associated with 4.6, 12.1, and 26.7-fold higher likelihood of opioid-related overdose (p<0.01). Patients with overlapping prescriptions during previous 0-30, 31-60, and 61-90 days were 13.2, 6.0, and 3.2-times more likely to experience an overdose (p<0.01).(11) |
CONZIP, FENTANYL, HYDROCODONE BITARTRATE ER, HYDROMORPHONE ER, HYSINGLA ER, MORPHINE SULFATE ER, MS CONTIN, NUCYNTA ER, OXYCODONE HCL ER, OXYCONTIN, OXYMORPHONE HCL ER, TRAMADOL HCL ER, XTAMPZA ER |
| Opioids (Immediate Release)/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use of opioids and benzodiazepines may result in additive CNS depression.(1) CLINICAL EFFECTS: Concurrent use of opioids and other CNS depressants, such as benzodiazepines, may result in profound sedation, respiratory depression, coma, and/or death.(1) PREDISPOSING FACTORS: Concurrent use of alcohol or other CNS depressants may increase the risk of adverse effects. PATIENT MANAGEMENT: Limit prescribing opioid analgesics with CNS depressants such as benzodiazepines to patients for whom alternatives are inadequate.(1) If concurrent use is necessary, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. If starting a CNS depressant (for an indication other than epilepsy) with an opioid analgesic, prescribe a lower initial dose of the CNS depressant than indicated in the absence of an opioid and titrate based upon clinical response. If an opioid analgesic is indicated in a patient already taking a CNS depressant, prescribe a lower dose of the opioid and titrate based upon clinical response.(1) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(2) Monitor patients receiving concurrent therapy for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(1) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(3) DISCUSSION: Between 2002 and 2014, the number of patients receiving an opioid analgesic increased 8%, from 75 million to 81 million patients, and the number of patients receiving a benzodiazepine increased 31%, from 23 million to 30 million patients. During this time, the proportion of patients receiving concurrent therapy increased 31%, from 23 million to 30 million patients.(4) From 2004 to 2011, the rate of nonmedical use-related emergency room visits involving both opioids and benzodiazepines increased from 11 to 34.2 per 100,000 and drug overdose deaths involving both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000. The proportion of prescription opioid analgesic deaths which also involved benzodiazepines increased from 18% to 31% during this time.(5) A prospective observational cohort study in North Carolina found that the rates of overdose death among patients co-dispensed opioid analgesics and benzodiazepines were 10 times higher than patients receiving opioid analgesics alone.(6) A case-cohort study of VA data from 2004-2009 found that the risk of death from overdose increased with concomitant opioid analgesics and benzodiazepines. Compared to patients with no history of benzodiazepines, patients with a history of benzodiazepine use (hazard ratio [HR] = 2.33) and patients with a current benzodiazepine prescription (HR=3.86) had an increased risk of fatal overdose.(7) A study found that opioid analgesics contributed to 77% of deaths in which benzodiazepines were determined to be a cause of death and that benzodiazepines contributed to 30% of deaths in which opioid analgesics were determined to be a cause of death. This study also found that other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) were contributory to death in many cases where opioid analgesics were also implicated.(8) A study found that alcohol was involved in 18.5% of opioid analgesic abuse-related ED visits and 22.1 percent of opioid analgesic-related deaths.(9) A study of 315,428 privately insured patients who filled at least one prescription for an opioid from 2001 to 2013 were enrolled in a retrospective study. Concurrent use of a benzodiazepine was recorded as having at least one day of overlap in a given calendar year. Baseline characteristics among opioid users with concurrent use of a benzodiazepine were older (44.5 v. 42.4, p<0.001), less likely to be men (35% v. 43%, p<0.001), and had a higher prevalence rate of every comorbidity examined (p<0.001). The proportion of opioid users with concurrent benzodiazepine use nearly doubled from 9% in 2001 to 17% in 2013. The primary outcome was an emergency room visit or inpatient admission for opioid overdose within a calendar year. Among all opioid users, the annual adjusted incidence for the primary outcome was 1.16% without concurrent benzodiazepine use compared to 2.42% with concurrent benzodiazepine use (OR 2.14; 95% CI 2.05-2.24; p<0.001). Intermittent opioid users (1.45% v. 1.02%; OR 1.42; 95% CI 1.33-1.51; p<0.001) and chronic opioid users (5.36% v. 3.13%; OR 1.81; 95% CI 1.67-1.96; p<0.001) also experienced a higher adjusted incidence of the primary outcome with concurrent benzodiazepine use compared to without concurrent benzodiazepine use, respectively.(10) In a nested case-control study of adults with a new opioid dispensing between 2010-2018, patients with concurrent use of an opioid with a benzodiazepine were significantly more likely to have opioid-related overdose compared to patients receiving opioids, benzodiazepines, or neither (OR 9.28; 95% CI 7.87, 10.93). Longer concurrent use of 1-7, 8-30, and 31-90 days was associated with 4.6, 12.1, and 26.7-fold higher likelihood of opioid-related overdose (p<0.01). Patients with overlapping prescriptions during previous 0-30, 31-60, and 61-90 days were 13.2, 6.0, and 3.2-times more likely to experience an overdose (p<0.01).(11) |
ACETAMIN-CAFF-DIHYDROCODEINE, ACETAMINOPHEN-CODEINE, APADAZ, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, BELLADONNA-OPIUM, BENZHYDROCODONE-ACETAMINOPHEN, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTORPHANOL TARTRATE, CARISOPRODOL-ASPIRIN-CODEINE, CODEINE PHOSPHATE, CODEINE SULFATE, DEMEROL, DIHYDROCODEINE BITARTRATE, DILAUDID, DSUVIA, DURAMORPH, ENDOCET, FENTANYL CITRATE, FENTANYL CITRATE-0.9% NACL, FENTANYL CITRATE-D5W, FENTANYL CITRATE-STERILE WATER, FENTANYL CITRATE-WATER, FENTANYL-BUPIVACAINE-0.9% NACL, FENTANYL-BUPIVACAINE-NACL, FENTANYL-ROPIVACAINE-0.9% NACL, FENTANYL-ROPIVACAINE-NACL, FIORICET WITH CODEINE, HYDROCODONE BITARTRATE, HYDROCODONE-ACETAMINOPHEN, HYDROCODONE-IBUPROFEN, HYDROMORPHONE HCL, HYDROMORPHONE HCL-0.9% NACL, HYDROMORPHONE HCL-D5W, HYDROMORPHONE HCL-NACL, HYDROMORPHONE HCL-WATER, INFUMORPH, LEVORPHANOL TARTRATE, MEPERIDINE HCL, MEPERIDINE HCL-0.9% NACL, METHADONE HCL, METHADONE HCL-0.9% NACL, METHADONE HCL-NACL, MITIGO, MORPHINE SULFATE, MORPHINE SULFATE-0.9% NACL, MORPHINE SULFATE-NACL, NALBUPHINE HCL, NALOCET, NUCYNTA, OLINVYK, OPIUM TINCTURE, OXYCODONE HCL, OXYCODONE HYDROCHLORIDE, OXYCODONE-ACETAMINOPHEN, OXYMORPHONE HCL, PENTAZOCINE-NALOXONE HCL, PERCOCET, PRIMLEV, PROLATE, QDOLO, REMIFENTANIL HCL, ROXICODONE, ROXYBOND, SUFENTANIL CITRATE, TRAMADOL HCL, TRAMADOL HCL-ACETAMINOPHEN, TREZIX, ULTIVA |
| Selected Benzodiazepines/Barbiturates SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Barbiturates and phenobarbital, CYP3A4 inducers, may induce the metabolism of some benzodiazepines. In addition, barbiturates, phenobarbital and benzodiazepines are CNS depressants. Primidone is metabolized to phenobarbital. CLINICAL EFFECTS: Concurrent or recent use of barbiturates or phenobarbital may result in decreased levels and loss of effectiveness of some benzodiazepines. Concurrent use of barbiturates and benzodiazepines may result in additive CNS depression (e.g. respiratory depression, increased somnolence). PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Monitor patients receiving phenobarbital or who have received doses in the previous 2 weeks for decreased benzodiazepine effectiveness. The dose of the benzodiazepine may need to be adjusted or an alternative agent used. Patients on chronic benzodiazepine therapy who are started on phenobarbital should be initially monitored for additive CNS sedation or respiratory depression, particularly when predisposing factors (e.g. COPD, sleep apnea, debilitation, elderly) are present. Continued use of phenobarbital leads to induction of benzodiazepine metabolism. The onset is gradual and may not peak for several weeks. If phenobarbital is discontinued, benzodiazepine levels will gradually rise as induction effects diminish. Monitor for increased benzodiazepine effects and adjust the dose accordingly. DISCUSSION: In a study in 95 healthy subjects, rifampin, a CYP3A4 inducer (450 mg daily for 5 days), decreased the plasma concentrations of a single oral dose of alprazolam (1 mg) by 79%.(1) In another study in 4 healthy subjects, rifampin (given for 4 days) decreased the area-under-curve (AUC) of a single oral dose of alprazolam (1 mg) by 88%.(2) In a double-blind, randomized, cross-over trial in 13 healthy subjects, rifampin (450 mg daily for 7 days) decreased the maximum concentration (Cmax), area-under-curve (AUC), and half-life of a single oral dose of brotizolam (0.5 mg) by 69%, 90%, and 69%, respectively. Concurrent rifampin increased scores on the Digit Symbol Substitution Test (DSST) and decreased scores on the Stanford Sleepiness Scale.(3) In a study in 21 healthy subjects, rifampin (600 mg or 1200 mg daily for 7 days) increased total body clearance of diazepam by 300%.(4) An in vitro study in human hepatocytes found that rifampin increased the biotransformation of diazepam and midazolam by 1.9-fold.(5) In a study in 24 healthy subjects, rifampin (600 mg daily for 10 days) increased the clearance of a single intravenous dose of lorazepam by 140%.(6) In an open-label cross-over study in 19 healthy subjects, rifampin (600 mg daily for 9 days) increased the clearance of a single oral dose of midazolam (0.075 mg/kg) by 7-fold.(7) In a study in 57 healthy subjects, rifampin increased the systemic and oral clearance of midazolam by 2-fold and 16-fold, respectively.(8) In a study in 8 healthy subjects, rifampin (given for 6 days) significantly increased the clearance of midazolam.(9) In a study in 9 healthy subjects, received a single oral dose of midazolam (15 mg) before, one day after the administration of rifampin (600 mg daily for 5 days), and 4 days after the last dose of rifampin. One day after rifampin, the AUC of midazolam was decreased by 97.7% when compared to the administration of midazolam prior to rifampin. Four days after the completion of rifampin, the AUC of midazolam was decreased by 87% when compared to the administration of midazolam prior to rifampin.(10) In a double-blind, randomized, cross-over study in 10 healthy subjects, rifampin (600 mg daily for 5 days) decreased the Cmax, AUC, and half-life of a single oral dose of midazolam (15 mg) by 94%, 96%, and 58%, respectively. The pharmacodynamic effects of midazolam were also significantly decreased during rifampin therapy.(11) In a study in 16 healthy subjects, rifampin (600 mg daily for 7 days) increased the clearance of nitrazepam by 83%. There were no significant effects on the pharmacokinetics of temazepam.(12) In a randomized, double-blind, cross-over study in 10 healthy subjects, rifampin (600 mg daily for 5 days) decreased the Cmax, AUC, and half-life of a single dose of triazolam (0.5 mg) by 87.6%, 94.9%, and 54%, respectively. The pharmacodynamic effects of triazolam were also significantly decreased during rifampin therapy.(13) In an open-label, randomized, cross-over study in 27 healthy subjects, rifaximin (200 mg three times daily for 7 days) had no effect on the pharmacokinetics of single doses of oral or intravenous midazolam.(14) In a study in 98 patients with schizophrenia or bipolar disorder, the expression of CYP3A4 was found to be the major determinant of clonazepam plasma concentrations normalized by the dose and bodyweight (1263 +/- 482.9 and 558.5 +/- 202.4 ng/mL per mg/kg bodyweight in low and normal expressers, respectively, p<0.0001).(18) |
ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, BUTALBITAL-ASPIRIN-CAFFEINE, DONNATAL, FIORICET, FIORICET WITH CODEINE, MYSOLINE, PENTOBARBITAL SODIUM, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PRIMIDONE, SEZABY, TENCON |
| Selected Opioids for MAT/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use of diacetylmorphine or methadone and benzodiazepines may result in additive CNS depression.(1,2) Levomethadone is an enantiomer of methadone.(3) CLINICAL EFFECTS: Concurrent use of diacetylmorphine or methadone and other CNS depressants, such as benzodiazepines, may result in profound sedation, respiratory depression, coma, and/or death.(1,2) PREDISPOSING FACTORS: Concurrent use of alcohol or other CNS depressants may increase the risk of adverse effects. PATIENT MANAGEMENT: Medication assisted treatment (MAT) with diacetylmorphine or methadone is not contraindicated in patients taking benzodiazepines or other CNS depressants; however, discontinuation of benzodiazepines and other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering may be appropriate. In others, gradual tapering or decreasing to the lowest effective dose of the benzodiazapine or CNS depressant is appropriate. Consider other medications and nonpharmacologic treatments to address anxiety or insomnia. Ensure that other health care providers prescribing benzodiazepines or other CNS depressants are aware of the patient's methadone treatment.(4) Respiratory depression can occur at any time during opioid therapy, especially during therapy initiation and following dosage increases. Consider this risk when using concurrently with other agents that may cause CNS depression.(5) Monitor patients receiving concurrent therapy for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(1) Educate patients about the risks of concurrent use and monitor for use of prescribed and illicit benzodiazepines or other CNS depressants.(4) Discuss naloxone with all patients when prescribing or renewing an opioid analgesic or medicine to treat opioid use disorder (OUD). Consider prescribing naloxone to patients prescribed medicines to treat OUD or opioid analgesics (such as those taking CNS depressants) who are at increased risk of opioid overdose and when a patient has household members/close contacts at risk for accidental overdose.(6) DISCUSSION: Between 2002 and 2014, the number of patients receiving an opioid analgesic increased 8%, from 75 million to 81 million patients, and the number of patients receiving a benzodiazepine increased 31%, from 23 million to 30 million patients. During this time, the proportion of patients receiving concurrent therapy increased 31%, from 23 million to 30 million patients.(7) From 2004 to 2011, the rate of nonmedical use-related emergency room visits involving both opioids and benzodiazepines increased from 11 to 34.2 per 100,000 and drug overdose deaths involving both opioids and benzodiazepines increased from 0.6 to 1.7 per 100,000. The proportion of prescription opioid analgesic deaths which also involved benzodiazepines increased from 18% to 31% during this time.(8) A prospective observational cohort study in North Carolina found that the rates of overdose death among patients co-dispensed opioid analgesics and benzodiazepines were 10 times higher than patients receiving opioid analgesics alone.(9) A case-cohort study of VA data from 2004-2009 found that the risk of death from overdose increased with concomitant opioid analgesics and benzodiazepines. Compared to patients with no history of benzodiazepines, patients with a history of benzodiazepine use (hazard ratio [HR] = 2.33) and patients with a current benzodiazepine prescription (HR=3.86) had an increased risk of fatal overdose.(10) A study found that opioid analgesics contributed to 77% of deaths in which benzodiazepines were determined to be a cause of death and that benzodiazepines contributed to 30% of deaths in which opioid analgesics were determined to be a cause of death. This study also found that other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) were contributory to death in many cases where opioid analgesics were also implicated.(11) A study found that alcohol was involved in 18.5% of opioid analgesic abuse-related ED visits and 22.1 percent of opioid analgesic-related deaths.(12) A study of 315,428 privately insured patients who filled at least one prescription for an opioid from 2001 to 2013 were enrolled in a retrospective study. Concurrent use of a benzodiazepine was recorded as having at least one day of overlap in a given calendar year. Baseline characteristics among opioid users with concurrent use of a benzodiazepine were older (44.5 v. 42.4, p<0.001), less likely to be men (35% v. 43%, p<0.001), and had a higher prevalence rate of every comorbidity examined (p<0.001). The proportion of opioid users with concurrent benzodiazepine use nearly doubled from 9% in 2001 to 17% in 2013. The primary outcome was an emergency room visit or inpatient admission for opioid overdose within a calendar year. Among all opioid users, the annual adjusted incidence for the primary outcome was 1.16% without concurrent benzodiazepine use compared to 2.42% with concurrent benzodiazepine use (OR 2.14; 95% CI 2.05-2.24; p<0.001). Intermittent opioid users (1.45% v. 1.02%; OR 1.42; 95% CI 1.33-1.51; p<0.001) and chronic opioid users (5.36% v. 3.13%; OR 1.81; 95% CI 1.67-1.96; p<0.001) also experienced a higher adjusted incidence of the primary outcome with concurrent benzodiazepine use compared to without concurrent benzodiazepine use, respectively.(13) In a nested case-control study of adults with a new opioid dispensing between 2010-2018, patients with concurrent use of an opioid with a benzodiazepine were significantly more likely to have opioid-related overdose compared to patients receiving opioids, benzodiazepines, or neither (OR 9.28; 95% CI 7.87, 10.93). Longer concurrent use of 1-7, 8-30, and 31-90 days was associated with 4.6, 12.1, and 26.7-fold higher likelihood of opioid-related overdose (p<0.01). Patients with overlapping prescriptions during previous 0-30, 31-60, and 61-90 days were 13.2, 6.0, and 3.2-times more likely to experience an overdose (p<0.01).(14) While concomitant use of MAT with CNS depressants increases the risk of adverse reactions, barriers to MAT can pose a greater risk of morbidity and mortality due to opioid use disorder.(4) |
DISKETS, METHADONE HCL, METHADONE INTENSOL, METHADOSE |
| Select Oral Benzodiazepines/Aprepitant (Less Than or Equal To 40 mg) SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Aprepitant doses greater than 40 mg per day are classified as moderate inhibitors of CYP3A4 and may inhibit the CYP3A4 mediated absorption and metabolism of alprazolam, midazolam or triazolam. Aprepitant doses < or = to 40 mg per day would be expected to inhibit CYP3A4 to a lesser extent.(1-3) CLINICAL EFFECTS: Concurrent administration of aprepitant may result in increased levels of and effects from the benzodiazepines.(1-4) Toxic effects of increased levels of benzodiazepines include profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Depending on patient tolerance, the benzodiazepine dosage may need to be reduced or an alternative agent not metabolized by CYP3A4 (e.g. lorazepam, temazepam) may be used. Patients receiving concurrent therapy with aprepitant and alprazolam, midazolam, or triazolam should be closely monitored and counseled regarding possible adverse effects due to increased benzodiazepine exposure. Due to its long half-life, the effects of a single dose of netupitant persist for 4 or more days. DISCUSSION: In an open-label, randomized single-period study in 16 healthy subjects, administration of aprepitant (125 mg on Day 1, 80 mg on Days 2-5) increased the area-under-curve (AUC) of a single oral dose of midazolam (2 mg on Day 1 and Day 5) by 2.3-fold on Day 1 and by 3.3-fold on Day 5 when compared to midazolam alone. Midazolam maximum concentration (Cmax) increased by 1.5-fold on Day 1 and by 1.9-fold on Day 5.(1,4) Midazolam half-life increased from 1.7 hours for midazolam alone to 3.3 hours on Day 1 and Day 5. In the second group, administration of aprepitant (40 mg on Day 1, 25 mg on Days 2-5) with midazolam had no significant effects on midazolam AUC, Cmax, or half-life.(5) In a study, administration of a single dose of aprepitant (40 mg) increased the AUC of a single dose of oral midazolam (2 mg) by 1.2-fold. This was not considered clinically significant.(1) In a study in 12 healthy subjects, administration of aprepitant (125 mg on Day 1, 80 mg on Days 2-3) increased the AUC of a single dose of intravenous midazolam (2 mg on Days 4, 8, and 15) by 25% on Day 4. The AUC of midazolam was decreased by 19% on Day 8. These effects were not considered clinically significant.(1,4) In a study, administration of a single dose of intravenous midazolam (2 mg) 1 hour after a single dose of aprepitant (125 mg) increased midazolam AUC by 1.5-fold.(1) |
APONVIE, APREPITANT |
| Benzodiazepines/Selected Stimulants SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Benzodiazepines and stimulants exhibit opposing effects on the CNS. CLINICAL EFFECTS: Concurrent use of benzodiazepine and stimulants may have unpredictable effects and may mask overdose symptoms of the benzodiazepine, such as drowsiness and inability to focus. PREDISPOSING FACTORS: Concurrent use of alcohol or other CNS depressants may increase the risk of adverse effects. PATIENT MANAGEMENT: Limit prescribing benzodiazepines with CNS stimulants such as amphetamines to patients for whom alternatives are inadequate. If concurrent use is necessary, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. Monitor patients receiving concurrent therapy for signs of substance abuse. DISCUSSION: Analysis of the 2015 and 2016 National Survey on Drug Use and Health found that misuse of benzodiazepines was strongly associated with misuse of or dependences on stimulants.(1) Benzodiazepines are used to reduce the adverse effects of stimulant use, such as insomnia.(2) Patients abusing benzodiazepines in combination with other drugs tend to consume higher dosages of benzodiazepines than patients abusing only benzodiazepines.(3) |
ADDERALL, ADDERALL XR, ADZENYS XR-ODT, AMPHETAMINE SULFATE, APTENSIO XR, AZSTARYS, CONCERTA, COTEMPLA XR-ODT, DAYTRANA, DESOXYN, DEXEDRINE, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE ER, DEXTROAMPHETAMINE-AMPHET ER, DEXTROAMPHETAMINE-AMPHETAMINE, DYANAVEL XR, EVEKEO, FOCALIN, FOCALIN XR, JORNAY PM, LISDEXAMFETAMINE DIMESYLATE, METADATE CD, METADATE ER, METHAMPHETAMINE HCL, METHYLIN, METHYLPHENIDATE, METHYLPHENIDATE ER, METHYLPHENIDATE ER (LA), METHYLPHENIDATE HCL, METHYLPHENIDATE HCL CD, METHYLPHENIDATE HCL ER (CD), MYDAYIS, PROCENTRA, QUILLICHEW ER, QUILLIVANT XR, RELEXXII, RITALIN, RITALIN LA, VYVANSE, XELSTRYM, ZENZEDI |
| Triazolam/Erythromycin; Fluconazole; Roxithromycin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Erythromycin, fluconazole and roxithromycin may inhibit the metabolism of triazolam through inhibition of CYP3A4. CLINICAL EFFECTS: Serum concentrations of triazolam may be increased, enhancing its pharmacological effects. Toxic effects of increased triazolam levels include profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should be cautioned about possible increased sedation and observed for this side effect. Decreasing the dose of the triazolam may be necessary. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: This interaction has been demonstrated in controlled studies involving concurrent oral administration of triazolam with erythromycin. Serum concentrations and the half-life of triazolam were increased by as much as 107%.(1) In a study of 12 healthy volunteers, erythromycin increased the maximum concentration (Cmax) and area-under curve (AUC) of triazolam by 1.8-fold and 3.65-fold, respectively.(2) In a study in eight subjects who were given triazolam with 50 mg, 100 mg, or 200 mg of fluconazole, the triazolam AUC increased by 1.6-fold, 2.1-fold, and 4.4-fold, respectively. The increase in triazolam half-life ranged from 1.3-fold to 2.3-fold. The Cmax of triazolam increased more than 2-fold when administered with 200 mg of fluconazole. The pharmacodynamic effects of triazolam were significantly increased by the 100 mg and 200 mg doses of fluconazole.(3) In a study in 12 subjects, fluconazole (200 mg) increased the AUC and half-life of triazolam by more than 2-fold. The pharmacodynamic effects were also increased.(4) |
DIFLUCAN, E.E.S. 200, E.E.S. 400, ERY-TAB, ERYPED 200, ERYPED 400, ERYTHROCIN LACTOBIONATE, ERYTHROCIN STEARATE, ERYTHROMYCIN, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN LACTOBIONATE, FLUCONAZOLE, FLUCONAZOLE-NACL |
| Gabapentinoids/Benzodiazepines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use may result in profound sedation, respiratory depression, coma, and/or death.(1-3) CLINICAL EFFECTS: Concurrent use of benzodiazepines may result in elevated levels of and toxicity from gabapentin and pregabalin, including profound sedation, respiratory depression, coma, and/or death.(1-3) PREDISPOSING FACTORS: Patients who are elderly, are taking other CNS depressants, have decreased renal function, and/or have conditions that reduce lung function (e.g. Chronic Obstructive Pulmonary Disease [COPD]) may be at a higher risk of this interaction. PATIENT MANAGEMENT: Limit prescribing benzodiazepines and gabapentinoids to patients for whom alternatives are inadequate.(1) If concurrent use is necessary, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. If starting a gabapentinoid with an benzodiazepine, prescribe a lower initial dose of the gabapentinoid than indicated in the absence of an opioid and titrate based upon clinical response. If a benzodiazepine is indicated (other than an indication of epilepsy) in a patient already taking a gabapentinoid, prescribe a lower dose of the benzodiazepine and titrate based upon clinical response.(1) Monitor patients receiving concurrent therapy for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.(1) DISCUSSION: Clinical trials have shown no pharmacokinetic interaction between pregabalin (300 mg BID) and lorazepam (1 mg single dose).(2) Among 49 case reports submitted to FDA over a 5 year period (2012-2017), 12 people died from respiratory depression with gabapentinoids. Two randomized, double-blind, placebo-controlled clinical trials in healthy people, three observational studies, and several studies in animals were reviewed. A trial showed that using pregabalin alone and using it with an opioid pain reliever can depress breathing function. Three observational studies showed a relationship between gabapentinoids given before surgery and respiratory depression occurring after surgery. Several animal studies also showed that pregabalin plus opioids can depress respiratory function. Benzodiazepines are expected to have a similar effect when used with gabapentinoids.(1) |
GABAPENTIN, GABAPENTIN ER, GABARONE, GRALISE, HORIZANT, LYRICA, LYRICA CR, NEURONTIN, PREGABALIN, PREGABALIN ER |
| Midazolam; Triazolam/Lenacapavir SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Lenacapavir is a moderate inhibitor of CYP3A4 and may decrease metabolism of midazolam and triazolam.(1-3) CLINICAL EFFECTS: Concurrent administration of lenacapavir and midazolam or triazolam may result in increased clinical effects (e.g. profound sedation, respiratory depression, coma, and/or death) of midazolam or triazolam.(1-3) CYP3A4 is the major or only hepatic metabolism pathway for the phase I elimination of midazolam. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of lenacapavir states concurrent use with midazolam or triazolam should be approached with caution.(1-3) Monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Concurrent administration of lenacapavir 600 mg with a single 2.5 mg dose of midazolam increased midazolam maximum concentration (Cmax) and area-under-curve (AUC) by 1.94-fold and 3.59-fold, respectively.(1-3) |
SUNLENCA, YEZTUGO |
The following contraindication information is available for TRIAZOLAM (triazolam):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Alcohol intoxication |
| Complex sleep behavior |
| Depression |
| Drug abuse |
| Pregnancy |
| Suicidal ideation |
There are 7 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Asthma |
| Chronic obstructive pulmonary disease |
| Disease of liver |
| Hypoalbuminemia |
| Myasthenia gravis |
| Psychotic disorder |
| Sleep apnea |
The following adverse reaction information is available for TRIAZOLAM (triazolam):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 35 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Muscle weakness |
Acute cognitive impairment Behavioral disorders CNS depression |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Accidental fall Agranulocytosis Anaphylaxis Anemia Angioedema Aplastic anemia Apnea Coma Depression Drug dependence Drug-induced psychosis Dyspnea Eosinophilia Hallucinations Hemolytic anemia Hostility Hypotension Jaundice Leukocytosis Leukopenia Manic disorder Memory impairment Neutropenic disorder Respiratory depression Seizure disorder Skin rash Sleep walking disorder Suicidal ideation Thrombocytopenic disorder Urinary retention |
There are 52 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Ataxia Dizziness Drowsy Dyspepsia Sedation Slurred speech |
Diarrhea Fatigue General weakness |
| Rare/Very Rare |
|---|
|
Aggressive behavior Agitation Alopecia Anorexia Anticholinergic toxicity Blurred vision Complex sleep behavior Concentration difficulty Conjunctivitis Constipation Cramps Delirium Depersonalization Diplopia Disturbance in thinking Dream disorder Dysarthria Dysuria Excitement Glossitis Headache disorder Hiccups Irritability Libido changes Menstrual disorder Nausea Nervousness Nightmares Nystagmus Paranoid disorder Polydipsia Pruritus of skin Sialorrhea Sleep disorder Stomatitis Syncope Tachycardia Tremor Urinary incontinence Vertigo Visual changes Xerostomia Yawning |
The following precautions are available for TRIAZOLAM (triazolam):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
It is not known whether triazolam is distributed into milk in humans; however, the drug and its metabolites are distributed into milk in rats. It is recommended that triazolam not be administered to nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for TRIAZOLAM (triazolam):
WARNING: Triazolam has a risk for abuse and addiction, which can lead to overdose and death. Taking this medication with alcohol or other drugs that can cause drowsiness or breathing problems (especially opioid medications such as codeine, hydrocodone) may cause very serious side effects, including death. To lower your risk, your doctor should have you take the smallest dose of triazolam that works, and take it for the shortest possible time.
Be sure you know how to take triazolam and what other drugs you should avoid taking with it. See also Drug Interactions section. Get medical help right away if any of these very serious side effects occur: slow/shallow breathing, unusual lightheadedness, severe drowsiness/dizziness, difficulty waking up.
Suddenly stopping this medication may cause serious (possibly fatal) withdrawal, especially if you have used it for a long time or in high doses. To prevent withdrawal, your doctor may lower your dose slowly. Tell your doctor or pharmacist right away if you have any withdrawal symptoms such as headaches, restlessness, hallucinations/confusion, depression, nausea, or seizures. Withdrawal symptoms may sometimes last weeks to months.
WARNING: Triazolam has a risk for abuse and addiction, which can lead to overdose and death. Taking this medication with alcohol or other drugs that can cause drowsiness or breathing problems (especially opioid medications such as codeine, hydrocodone) may cause very serious side effects, including death. To lower your risk, your doctor should have you take the smallest dose of triazolam that works, and take it for the shortest possible time.
Be sure you know how to take triazolam and what other drugs you should avoid taking with it. See also Drug Interactions section. Get medical help right away if any of these very serious side effects occur: slow/shallow breathing, unusual lightheadedness, severe drowsiness/dizziness, difficulty waking up.
Suddenly stopping this medication may cause serious (possibly fatal) withdrawal, especially if you have used it for a long time or in high doses. To prevent withdrawal, your doctor may lower your dose slowly. Tell your doctor or pharmacist right away if you have any withdrawal symptoms such as headaches, restlessness, hallucinations/confusion, depression, nausea, or seizures. Withdrawal symptoms may sometimes last weeks to months.
The following icd codes are available for TRIAZOLAM (triazolam)'s list of indications:
| Insomnia | |
| F51.0 | Insomnia not due to a substance or known physiological condition |
| F51.01 | Primary insomnia |
| F51.02 | Adjustment insomnia |
| F51.03 | Paradoxical insomnia |
| F51.04 | Psychophysiologic insomnia |
| F51.05 | Insomnia due to other mental disorder |
| F51.09 | Other insomnia not due to a substance or known physiological condition |
| G47.0 | Insomnia |
| G47.00 | Insomnia, unspecified |
| G47.01 | Insomnia due to medical condition |
| G47.09 | Other insomnia |
Formulary Reference Tool